Program-Level Neoadjuvant Chemotherapy Use and 10-Year Survival in Advanced Ovarian Cancer
Open access0 citations
Abstract
This comparative effectiveness research examines the association between neoadjuvant chemotherapy adoption by US cancer programs and 10-year survival among patients with advanced ovarian cancer.
// Source
Authors: Alex E. R. Powers, Gretchen Davis, D. Jenkins, Alicia Youssef, William Manning, Jason D. Wright, NL Keating, Amy Bregar, Alejandro Rauh-Hain, Alexander Melamed
Institutions: Harvard University, Tufts University, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Mass General Brigham